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Why was the cohort set up?  
Chronic obstructive pulmonary disease (COPD) affects 5-10% of people worldwide (1), is rising in 
prevalence (2) and is the third most common cause of death (3). The annual burden of COPD 
regarding healthcare (mainly exacerbations resulting in emergency admissions)  and societal 
(predominantly lost productivity) costs was estimated to be around $49.9billion in the USA (2010 
prices (4)) and €48.4billion in the EU (2011 prices (5)). A substantial proportion of those with COPD 
are of working age, but there is some evidence that they have poorer employment history  (6), 
higher rate of sickness absence (7) and  poorer work performance (presenteeism) (8) compared to 
the general population. 
There remains much uncertainty about the natural history of COPD (9, 10) and which interventions 
are effective in altering the course of early disease. Furthermore, up to 85% of cases (11-13) are 
undiagnosed; representing many with potentially unmet need. Partly in response to reports (14-16) 
highlighting the burden of COPD, extent of underdiagnosis and uncertainty about prognosis of early 
disease, expert reviews have highlighted a need for further longitudinal data (9, 10). However, 
established cohorts usually represent secondary care patients with more advanced disease, with 
short duration of follow up and, generally small samples (17-19). While large population cohorts 
have sometimes addressed questions relevant to COPD (20-28), limitations in outcome measures 
and quality of lung function testing provide insufficient data to inform the COPD arena. Importantly, 
there are no primary care COPD cohorts with case-found patients and few with patients 
representing the full range of disease severity, particularly those with mild to moderate disease, and 
diverse socioeconomic mix.  
In recent years, several studies have also focused on patients reporting respiratory symptoms but 
who have normal lung function (former GOLD severity stage 0 (29)). The evidence on progression to 
COPD is limited and contradictory (23, 30, 31) and methods for assessing symptoms are inconsistent 
(23, 32). Thus there is also a paucity of evidence on the clinical relevance and natural history for this 
patient group. 
Better understanding of natural history and prognostic factors is needed to facilitate consultations, 
and to inform management decisions and health service planning. Existing COPD prognostic indices 
(PI) mainly focus on predicting mortality risk (17, 33-36), though others were developed to predict 
additional outcomes such as exacerbations (37, 38), COPD-related hospitalisation (39), respiratory 
hospital attendance/admission (40), exacerbation or hospitalisation (41, 42). Only three indices (38, 
41, 42) were derived in primary care populations despite this being where most COPD patients are 
managed, and most included patients with more severe established disease. No indices were 
developed in populations that included case-found patients. The methods and basis for selecting 
prognostic variables are rarely described, and the feasibility of obtaining all the required measures in 
non-specialist settings is not always considered.  The paucity of evidence from the primary care 
setting as well as the other limitations suggests that further validation is required. Furthermore, the 
low discriminatory ability of most of the existing indices suggests that other important potential 
measures (e.g. co-morbidities, occupation or serum inflammatory markers) may need to be 
considered to improve prognostic prediction and usefulness of the indices.   
Our prospective cohort study with an initial three-year follow up period, allows cross-sectional and 
longitudinal analyses. The aim is to identify the most appropriate COPD prognostic index for use in a 
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primary care population (with all cause hospitalisation as primary, and respiratory hospitalisation, 
exacerbations, primary care consultations and mortality as secondary outcomes), to examine factors 
associated with employment and work productivity among those with COPD of working age, to 
develop a platform to test novel interventions and to provide a data source for additional analyses of 
relevance to patient benefit.  
Funding and ethical approval 
This paper summarises independent research funded by the National Institute for Health Research 
(NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-
PG-0109-10061). The views expressed are those of the authors and not necessarily those of the NHS, 
the NIHR or the Department of Health. The Birmingham COPD Cohort study is part of The 
Birmingham Lung Improvement StudieS – BLISS. The cohort received ethical approval from the 
National Research Ethics Service Committee West Midlands - Solihull (ref: 11/WM/0304).  
Who is in the cohort? 
Patients were recruited from 71 General Practices (GP) across the West Midlands, UK and include 
three patient groups: those with diagnosed COPD according to GP records (prevalent cases), 
previously undiagnosed patients with respiratory symptoms and airflow obstruction confirmed by 
spirometry (incident cases) and symptomatic patients with normal lung function confirmed by 
spirometry (‘symptomatic normals’). The latter two groups were identified through a linked case-
finding trial (43).  
To inform prognostic model development, we aimed to recruit 2000 patients. The sample size 
assumes that 25% of COPD patients will be hospitalised in the three-year period, a 30% loss-to-
follow up and 12% three-year mortality. 
Identifying potentially eligible patients 
The process of identifying eligible patients differed according to the patient group. The sampling 
frame for the prevalent cases comprised patients aged 40 years and over, with diagnosed COPD. 
Standardised electronic searches were conducted in participating practices to identify patients on 
the COPD QoF register (COPD14). The resulting lists were screened by a clinician who excluded 
patients deemed unsuitable due to terminal illness, being housebound, inability to give informed 
consent and other adverse social factors (e.g. recent bereavement, alcohol dependency). 
A full description of the eligibility criteria for the case-finding trial was published previously (43). In 
brief, eligible patients were aged 40 to 79 who reported relevant respiratory symptoms on a 
screening questionnaire. Patients were subsequently invited to the Cohort study if, they had 
indicated willingness to be contacted about other studies.  
Patient recruitment 
Eligible patients were sent an invitation letter and study information sheet from their GP, with up to 
two reminders to non-responders. Interested patients were invited to an assessment visit at either 
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their General Practice or alternative local health centre, where informed consent was obtained 
(Figure 1).  
[Figure 1 here] 
Generalisability of cohort 
Basic demographic data (sex, age and ethnicity) were obtained for all identified eligible patients 
from their primary care records (Table 1). Overall, those who consented to take part were more 
likely to be male and of White British ethnicity. Among prevalent cases, those who consented were 
slightly younger than other eligible patients, whereas the reverse was true for those identified 
through case-finding.  
[Table 1 here] 
Sample characteristics 
Prevalent cases were older, more likely to be of White British ethnicity, less likely to be in paid 
employment and more deprived compared with the other two patient groups (Table 2). The 
observed differences may be due in part to the previously described eligibility criteria for the case-
finding trial. Prevalent and incident cases were more likely to be male (61.6% and 61.0% 
respectively), but the sex-distribution was similar (52.8% male) in symptomatic normals. Incident 
cases had the highest proportion of current smokers (33.6%), compared with prevalent (28.3%) and 
symptomatic normals (19.4%). Only 10.4% of prevalent cases were never smokers compared with 
incident cases (14.7%) and symptomatic normals (19.1%).  
[Table 2 here] 
How often have they been followed up?  
Patients receive six-monthly postal questionnaires (at 6, 12 18, 24, 30 months), with one reminder to 
non-responders. Follow-up study assessment visits (from March 2015) will be arranged three years 
after baseline, or as close as is feasible within the study period. We plan to apply for additional 
funding to extend the follow-up period beyond the initial three years.  
What has been measured?  
Baseline assessment visits, lasting an average of 90 minutes, were conducted by trained research 
assistants, using standardised protocols and recording data on a standardised Case Report Form. A 
high standard for spirometry training was achieved using a short modified programme modelled on 
the ARTP Spirometry course by the lung function unit at Queen Elizabeth Hospital Birmingham. 
Refresher training, quality monitoring and feedback were undertaken throughout the study. 
Research assistants were also trained in study-specific measures, phlebotomy and Good Clinical 
Practice (GCP).  
Lung function was assessed using the ndd Easy One spirometer (ndd, Switzerland), before and 20 
minutes after administration of 400 micrograms Salbutamol. A minimum of three and a maximum of 
eight blows pre-bronchodilator and six blows post-bronchodilator were permitted, or less if 
repeatability within 100mls was achieved, after which the best result was taken. Customised 
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software (MMiller) was used to ensure real-time display of volume-time and flow-volume graphs for 
quality assessment. At baseline, all traces were over-read and data for forced expiratory volume in 1 
second (FEV1) and forced vital capacity (FVC) were considered usable if they met ATS acceptability 
criteria and were reproducible to within 200 ml.  A summary of prognostic, outcome and other 
variables assessed by either direct measurement or through questionnaires, is provided in Table 3. 
Height was measured to the nearest 0.1cm using a Leicester height monitor, and weight (to the 
nearest 0.1kg) and body fat were assessed using Tanita BC-420SMA body composition scale. Grip 
strength was measured to the nearest 1kg with a Saehan hydraulic hand dynamometer. Exercise 
capacity was assessed using the sit-to-stand test, which has been shown to be a valid alternative to 
the 6-minute walk test (44) and is more practical in primary care settings.  
Data from occupational measures will contribute towards a nested study, to be reported separately.  
[Table 3 here] 
What has been found? Key findings and publications 
Key findings: 
While there is broad consensus that the Lower Limit of Normal (LLN) should be used instead of the 
fixed ratio (FEV 1/FVC<70%) for defining airflow obstruction (AO) in epidemiological studies (45, 46), 
we present data for both criteria. Using the fixed ratio allows comparability with i) UK primary care 
practice in accordance to guidelines (47) and ii) other studies, which historically have used this 
definition. Our assessment visit spirometry confirmed AO in only 86.4% of prevalent cases using the 
fixed ratio criteria and 71.9% using LLN (Table 4). Lung function variability was also evident in 
patients recruited from the linked case-finding trial, even though spirometry in both studies was 
conducted by identically-trained researchers, using the same spirometers and protocols. At the 
Cohort baseline assessment, 81.2% of previously-defined incident cases and 14.0% of previously-
defined symptomatic normals had AO (using the fixed ratio). The observed discrepancies may be 
explained in part by within-test reproducibility of FEV1 and FVC (repeatability) (48) and between-test 
variation in bronchodilator response (reversibility) (49); however among prevalent cases it could also 
indicate misdiagnosis, which will be explored in a subsequent paper.  
The baseline characteristics of the prevalent, incident and symptomatic normal patients are 
summarised in Table 5. Compared with other groups, prevalent cases have more severe AO (23.6% 
versus 1.8% were GOLD stages 3-4), a higher rate of reporting chronic bronchitis (symptoms of 
cough and phlegm for as much as three consecutive months each year), wheeze, and severe 
dyspnoea (~⅔ reporting MRC grade 3-5, compared to ⅓ among other groups).  
Prevalent cases also reported worse general (EQ5-D) and disease-specific (CAT) health-related 
quality of life. Compared with incident cases, those with prevalent COPD had lower exercise 
capacity, a higher frequency of exacerbations (defined as having a course of prescribed antibiotics or 
systemic steroids alone, or in combination (50)) over the previous year, and higher rates of all-cause 
and respiratory-related hospitalisations. However, the prevalence of major diagnosed co-morbidities 
(including diabetes, cardiovascular disease, osteoporosis, fractures, depression or peptic ulcers) did 
not differ between groups. 
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Overall, 4.2% of the cohort were underweight, and over a third were obese. The proportion 
underweight was greatest among prevalent cases (5.1%), whereas obesity was most common among 
the symptomatic normals (46.4%).  
[Table 4 here] 
Multivariable analyses adjusting for sex, age, smoking status and severity of AO, were undertaken to 
compare characteristics of prevalent and incident cases (Table 5). Incident cases were half as likely 
to report chronic cough and wheeze compared with prevalent cases, though no difference was 
found regarding chronic bronchitis or presence of co-morbidities. Incident cases were less likely to 
report severe dyspnoea (MRC grades 3-5), had higher generic and disease specific quality of life 
scores, higher BODE1 index, indicating lower mortality risk and fewer all-cause and respiratory-
related hospitalisations.  
Restricting the analyses to patients with confirmed airway obstruction at the cohort baseline 
assessment for the prevalent and incident cases did not alter the direction of the findings, although 
the magnitude of effect altered slightly.  
The above analysis confirms that incident cases identified through case-finding have less severe 
disease. Nevertheless, the majority (84%; 278/331) of incident cases have the potential to benefit 
from having been identified, if evidence-based interventions are administered. One third were 
current smokers and would benefit from intensive smoking cessation interventions. Over a third 
reported severe (MRC grade 3-5) dyspnoea, with potential to benefit from pulmonary rehabilitation 
(47) and over half reported symptoms of chronic cough, which can be responsive to 
pharmacotherapy (47). Longitudinal follow-up is needed to assess whether these potential benefits 
of early diagnosis are realised. 
The data also highlight the need to explore the symptomatic normals that report comparable co-
morbidities to other groups, and are similar to incident patients in respect of dyspnoea, CAT and EQ-
5D scores as well as history of hospitalisations. Longitudinal analyses will determine whether 
symptomatic normals represent a pre-COPD stage, and if so, which factors affect future prognosis.  
[Table 5 here] 
Publications: 
The study design and interim analyses have been presented at several international meetings 
including COPD8 in 2012, the Annual Congresses of the European Respiratory Society in 2013 (51) 
and 2014 (52), the World Conference of the International Primary Care Respiratory Group 2014 and 
the International Conference of the American Thoracic Society 2014 (53). Other print publications 
are in preparation.  
What are the main strengths and weaknesses?  
The inclusion of case-found patients provides the novel opportunity to characterise and follow a 
subgroup of previously undiagnosed COPD patients, many of whom have mild to moderate COPD 
and were under-represented in previous cohort studies.  
                                                          
1 Calculated using sit-to-stand rather than 6-minute walk, due to space restrictions within GP surgeries 
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Establishing a large primary care COPD cohort and assessing a wide range of outcomes will enable us 
to test the external validity of existing prognostic indices (PI), and if necessary adapt or develop a 
new PI suitable for use in the primary care setting.  
A further strength is the inclusion of symptomatic patients with normal lung function. Longitudinal 
data on this patient group may identify modifiable factors affecting progression. As with other 
chronic diseases, early detection and management of such patients may prevent or delay 
progression of the condition.   
Conducting the study assessments within General Practices was a pre-requisite, due to the 
administration of Salbutamol to assess reversibility. Unfortunately this requirement precluded 
housebound patients from participating, who may have had more severe COPD. Thus the findings 
are likely to be more relevant to an ambulatory primary care COPD population, with predominantly 
mild to moderate disease.  
Despite the setting, ethnic diversity within our cohort was limited. Although a translated cover sheet 
was enclosed at initial invitation, lack of resources prohibited  use of multiple recruitment strategies, 
such as snowball sampling, peer researchers and contact with key community leaders (54), which 
may have boosted recruitment of those for whom English was not their first language.  
Can I get hold of the data? Where can I find out more?  
The data are held by the BLISS research team at the University of Birmingham. Copies of the 
questionnaires, measurement procedures and administrative processes are available on request, 
through our website (www.birmingham.ac.uk/bliss).  Copies of published and in-press papers will 
also be available on the website. Potential collaborators should contact the programme manager or 
the principal investigators in the first instance, before completing a formal New Research Proposal 
pro forma (see website for details). Proposals are assessed for feasibility, potential overlap with 
ongoing work and cost to participants. Successful collaborations to date include projects between 
research team members and others with complementary skills both within and external to the 
University of Birmingham (see website for details) and hosting of post-graduate research students. 
We very much welcome new opportunities for collaboration. 
Birmingham COPD Cohort study profile in a nutshell:  
• This is the first primary care based cohort of COPD patients including both existing and case-
found patients, as well as those with chronic respiratory symptoms  and normal lung function 
• This prospective cohort study will identify the most appropriate prognostic index for use in a 
primary care COPD population, which best predicts risk of hospital admission  
• A total of 2302 patients aged 40 and above were recruited from 71 General Practices across the 
West Midlands, UK and include: those with diagnosed COPD, previously undiagnosed patients 
with respiratory symptoms and airflow obstruction confirmed by spirometry and symptomatic 
patients with normal lung function confirmed by spirometry. 
• Clinical assessments were conducted at baseline (2012-2014) and three-year follow-up, with 
postal questionnaires completed at six-monthly intervals. 2107 patients remained eligible on 
commencement of follow-up assessments. 
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• Data collected includes spirometry, physiological and anthropometric measures, as well as 
biological samples, self-completed questionnaires and linkage to health and social care data. 
• We welcome new opportunities for collaboration and copies of the questionnaires, 
measurement procedures and administrative processes are available on request, through our 
website. 
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Figure 1: Flowchart summarising patient recruitment and assessment for the Birmingham COPD Cohort Study 
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Table 1: Demographic characteristics of cohort participants from primary care records, comparing consented with non-consented patients 
 Prevalent cases Incident cases & symptomatic normal patients 
(symptomatic patients identified through case-
finding) 
 Consented participants 
(n=1558) 
Eligible, not consented 
(n=4825) 
Consented participants 
(n=744) 
Eligible, not consented 
(n=1285) 
Age – mean (SD) 69.0 (9.4) 69.8 (11.0) 62.3 (9.6) 59.2 (10.9) 
Age categories – n (%) 
40-49yrs 
50-59yrs 
60-69yrs 
70-79yrs 
80-89yrs 
90yrs+ 
 
55 (3.5) 
188 (12.1) 
596 (38.3) 
522 (33.5) 
191 (12.3) 
6 (0.4) 
 
212 (4.4) 
721 (14.9) 
1445 (30.0) 
1521 (31.5) 
837 (17.4) 
89 (1.8) 
 
97 (13.0) 
182 (24.5) 
273 (36.7) 
192 (25.8) 
n/a* 
n/a* 
 
330 (25.7) 
340 (26.5) 
360 (28.0) 
255 (19.8) 
n/a* 
n/a* 
Sex 
Male 
Female 
 
959 (61.6) 
599 (38.5) 
 
2415 (50.1) 
2410 (50.0) 
 
417 (56.1) 
327 (44.0) 
 
667 (51.9) 
618 (48.1) 
Ethnicity     
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White British 
Mixed 
Asian 
African/Caribbean 
Other 
Unclear/missing 
1120 (71.9) 
3 (0.2) 
17 (1.1) 
5 (0.3) 
43 (2.8) 
370 (23.8) 
3287 (68.1) 
14 (0.3) 
85 (1.8) 
42 (0.9) 
149 (3.1) 
1248 (25.9) 
477 (64.1) 
5 (0.7) 
23 (3.1) 
13 (1.8) 
4 (0.5) 
222 (29.8) 
788 (61.3) 
12 (0.9) 
73 (5.7) 
32 (2.5) 
12 (0.9) 
368 (28.6) 
* Upper age limit of 79 years due to eligibility for the case-finding trial 
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Table 2: Baseline self-reported demographics for whole cohort, then split by patient group 
 All cohort 
(n=2302) 
Prevalent 
(n=1558) 
Incident 
(n=331) 
Symptomatic 
normal LF 
(n=413) 
Age – mean (SD) 67.3 (9.9) 69.2 (9.4) 65.3 (8.7) 61.8 (10.0) 
Age categories – n (%) 
40-49yrs 
50-59yrs 
60-69yrs 
70-79yrs 
80-89yrs 
90yrs+ 
 
128 (5.6) 
362 (15.7) 
851 (37.0) 
749 (32.5) 
206 (9.0) 
6 (0.3) 
 
50 (3.2) 
183 (11.8) 
586 (37.6) 
530 (34.0) 
203 (13.0) 
6 (0.4) 
 
19 (5.7) 
69 (20.9) 
127 (38.4) 
115 (34.7) 
1 (0.3)†† 
- 
 
59 (14.3) 
110 (26.6) 
138 (33.4) 
104 (25.2) 
2 (0.5)†† 
- 
Sex – n (%) male 1379 (59.9) 959 (61.6) 202 (61.0) 218 (52.8) 
Ethnicity – n (%) 
White British 
Mixed 
Asian 
African/Caribbean 
Other 
No clear answer/missing 
 
2034 (88.4) 
13 (0.6) 
53 (2.3) 
23 (1.0) 
1 (0.04) 
178 (7.7) 
 
1391 (89.3) 
5 (0.3) 
28 (1.8) 
10 (0.6) 
- 
124 (8.0) 
 
291 (87.9) 
2 (0.6) 
8 (2.4) 
4 (1.2) 
- 
26 (7.9) 
 
352 (85.3) 
6 (1.5) 
17 (4.1) 
9 (2.2) 
1 (0.2) 
28 (6.8) 
Employment – n (%) 
In work 
Not in work 
 
503 (22.1) 
1776 (77.9) 
 
248 (16.1) 
1296 (83.9) 
 
98 (30.0) 
229 (70.0) 
 
157 (38.5) 
251 (61.5) 
Deprivation quintiles†– n (%) 
Quintile 1 
Quintile 2 
Quintile 3 
Quintile 4 
 
569 (24.7) 
581 (25.2) 
450 (19.6) 
389 (16.9) 
 
411 (26.4) 
404 (25.9) 
261 (16.8) 
280 (18.0) 
 
73 (22.1) 
78 (23.6) 
88 (26.6) 
49 (14.8) 
 
85 (20.6) 
99 (24.0) 
101 (24.5) 
60 (14.5) 
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Quintile 5 313 (13.6) 202 (13.0) 43 (13.0) 68 (16.5) 
Smoking status – n (%) 
Current 
Ex 
Never 
 
583 (27.4) 
1276 (60.0) 
268 (12.6) 
 
404 (28.3) 
876 (61.3) 
148 (10.4) 
 
103 (33.6)  
159 (51.8)  
45 (14.7)  
 
76 (19.4)  
241 (61.5)  
75 (19.1)  
†Based on the Index of Multiple Deprivation (IMD) 2010; with higher quintiles indicating less deprivation. 
Quintiles based on data for the West Midlands, UK 
††Patients had their 80th birthday between the Cohort invitation and baseline assessment 
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Table 3: Prognostic and outcome measures 
Phase Measures and example questionnaires 
Baseline assessment 
(2012-2014) 
Spirometry: pre- and post-bronchodilator, 400µg Salbutamol via large volume spacer 
Anthropometry: height, weight, bioimpedance, arm span, waist/hip/neck 
circumference 
Physiology: sit-to-stand test, hand grip strength, blood pressure, heart rate, oxygen 
saturation, breathlessness on exertion (BORG scale) 
Blood samples: DNA, serum and plasma aliquots stored at -80°C 
Self-completed questionnaires: demographics, lifestyle, home environment, HRQoL 
(e.g. SGRQ-C (55), EQ-5D 5L (56), CAT (57), MRC (58)), general health, exacerbations, 
health care usage, exercise (IPAQ – short (59)), physician-diagnosed medical conditions 
(comorbidities), depression (PHQ-9 (60)) 
Interviewer-led questionnaire: current medications, occupational history, 
presenteeism (SPS-6 (61), WPAI (62)) 
Six-monthly 
questionnaires  
(2012-2015) 
Self-completed questionnaire only: lifestyle, home environment, HRQoL (e.g. SGRQ-C, 
EQ-5D 5L, CAT, MRC), general health, exacerbations, health care usage, exercise (IPAQ 
- short), medical conditions, depression (PHQ-9), medications, occupation, 
presenteeism (SPS-6) 
Follow-up 
assessment  
(2015-2016) 
Spirometry: 400µg Salbutamol via large volume spacer, post-bronchodilator 
Anthropometry: height, weight, bioimpedance, arm span, waist circumference 
Physiology: sit-to-stand test, hand grip strength, oxygen saturation, breathlessness on 
exertion (BORG scale) 
Self-completed questionnaires: demographics, lifestyle, home environment, HRQoL 
(e.g. SGRQ-C, EQ-5D 5L, CAT, MRC), general health, exacerbations, health care usage, 
exercise (IPAQ - short), medical conditions, depression (PHQ-9), medications, 
occupation 
Routine data 
(2015-2016) 
General Practitioner records: co-morbidities, test results, referrals, medication 
HSCIC data: deaths and hospital episodes since 2012 
HRQoL = health-related quality of life, SGRQ-C = St George's Respiratory Questionnaire-Short, EQ-5D 5L = 
EuroQol 5 dimensions 5-level version, CAT = COPD Assessment Test, MRC = Medical Research Council 
Dyspnoea Scale, IPAQ – short = International Physical Activity Questionnaire, PHQ-9 = Patient Health 
Questionnaire, SPS-6 = Stanford Presenteeism Scale, WPAI = Work Productivity and Activity Impairment 
Questionnaire, HSCIC = Health and Social Care Information Centre 
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Table 4: Baseline airway obstruction for whole cohort, then split by patient group 
 All cohort 
(n=2302) 
Prevalent 
(n=1558) 
Incident 
(n=331) 
Symptomatic 
normal LF 
(n=413) 
Airway obstruction – LLN (GLI) 1259 (57.5) 1059 (71.9) 181 (56.7) 19 (4.8) 
Airways obstruction  – FR 1587 (72.4) 1272 (86.4) 259 (81.2) 56 (14.0) 
GOLD stage if <FR – n (%) 
  1 (FEV1 ≥ 80% pred) 
  2 (50-79%) 
  3 (30-49%) 
  4 (<30%) 
 
515 (32.5) 
766 (48.3) 
260 (16.4) 
46 (2.9) 
 
311 (24.5) 
661 (52.0) 
254 (20.0) 
46 (3.6) 
 
160 (61.8) 
94 (36.3) 
5 (1.9) 
- 
 
44 (78.6) 
11 (19.6) 
1 (1.8) 
- 
LLN = lower limit of normal, GLI = Global Lungs Initiative, GOLD = Global Initiative for chronic Obstructive Lung 
Disease, FR = fixed ratio (FEV1/FVC), FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity 
Lower Limit of Normal (LLN) is defined as the lowest 5th percentile of predicted FEV1 values for a healthy 
population 
Fixed Ratio is defined as FEV1/FVC <0.70 
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Table 5: Characteristics and health care use of cohort participants at baseline, comparing prevalent, incident and symptomatic normals 
 All cohort 
(n=2302) 
Prevalent 
(n=1558) 
Incident 
(n=331) 
Symptomatic 
normal LF (n=413) 
Adjusted odds ratio (95% CI); 
p value¥ 
Chronic cough – n (%) yes 1273 (56.9) 944 (62.4) 157 (48.6) 172 (42.6) 0.53 (0.41, 0.69); <0.001 
Chronic phlegm – n (%) yes 978 (43.7) 747 (49.4) 116 (35.9) 115 (28.5) 0.56 (0.43, 0.74); <0.001 
Chronic cough / chronic phlegm – n 
(%) yes 
1340 (59.9) 991 (65.5) 167 (51.7) 182 (45.1) 0.53 (0.40, 0.69); <0.001 
Wheeze – n (%) yes 1490 (66.7) 1111 (73.5) 194 (60.1) 185 (46.3) 0.50 (0.38, 0.66); <0.001 
MRC dyspnoea – n (%) 
Grade 1-2 
Grade 3-5 
 
1013 (46.8) 
1154 (53.2) 
 
551 (37.8) 
908 (62.2) 
 
206 (64.8) 
112 (35.2) 
 
256 (65.6) 
134 (34.4) 
0.42 (0.32, 0.55); <0.001 
Asthma – n (%) yes 881 (39.9) 617 (46.0) 87 (28.8) 107 (27.5) 0.40 (0.30, 0.54); <0.001 
Cardiovascular disease – n (%) yes 1239 (59.2) 871 (62.5) 171 (55.2) 197 (50.8) 0.93 (0.71, 1.23); 0.62 
Co-morbidities – n (%) 
None 
1 
2 
3 or more 
 
598 (26.0) 
767 (33.3) 
558 (24.2) 
379 (16.5) 
 
401 (25.7) 
511 (32.8) 
370 (23.8) 
276 (17.7) 
 
92 (27.8) 
114 (34.4) 
81 (24.5) 
44 (13.3) 
 
105 (25.4) 
142 (34.4) 
107 (25.9) 
59 (14.3) 
0.90 (0.67, 1.20); 0.46α 
21 
 
Exacerbations – n (%) 
None 
1 
2 
3 or more 
 
1126 (52.0) 
377 (17.4) 
305 (14.1) 
356 (16.5) 
 
574 (39.4) 
293 (20.1) 
262 (18.0) 
329 (22.6) 
 
234 (74.5) 
45 (14.3) 
21 (6.7) 
14 (4.5) 
 
318 (81.1) 
39 (10.0) 
22 (5.6) 
13 (3.3) 
0.25 (0.19, 0.34); <0.001α 
Weight status – n (%) 
   Underweight (BMI<20) 
   Healthy (20-25) 
   Overweight (25-30) 
   Obese (30+)  
 
90 (4.2) 
465 (21.5) 
823 (38.1) 
784 (36.3) 
 
76 (5.1) 
346 (23.2) 
571 (38.3) 
499 (33.5) 
 
9 (3.1) 
62 (21.3) 
111 (38.1) 
109 (37.5) 
 
5 (1.3) 
57 (15.0) 
141 (37.2) 
176 (46.4) 
0.95 (0.45, 20.2); 0.89α 
BODE†† score – n (%) 
    0-2 
    3-4 
    5-6 
    7-10 
 
732 (44.2) 
480 (29.0) 
297 (17.9) 
148 (8.9) 
 
361 (32.4) 
356 (31.9) 
252 (22.6) 
146 (13.1) 
 
158 (66.1) 
65 (27.2) 
16 (6.7) 
- 
 
213 (70.3) 
59 (19.5) 
29 (9.6) 
2 (0.7) 
0.44 (0.32, 0.60); <0.001α 
All-cause hospitalisations in previous 
12 months – n (%) yes 
315 (14.7) 251 (17.4) 29 (9.3) 35 (8.9) 0.64 (0.42, 0.99); <0.05 
Respiratory hospitalisations in 114 (5.3) 103 (7.0) 3 (1.0) 8 (2.0) 0.24 (0.07, 0.77); <0.05 
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previous 12 months – n (%) yes  
 All cohort 
(n=2302) 
Prevalent 
(n=1558) 
Incident 
(n=331) 
Symptomatic 
normal LF (n=413) 
Adjusted mean difference 
(95% CI); p value¥ 
CAT score – mean (SD) 18.0 (8.8) 20.0 (8.8) 14.4 (7.41) 14.1 (7.7) -4.5 (-5.74, -3.30); <0.001 
EQ-5D 5L score – mean (SD)  0.72 (0.2) 0.69 (0.2) 0.78 (0.2) 0.75 (0.2) 0.07 (0.04, 0.10); <0.001 
Sit-to-Stand test – mean (SD) 19.3 (6.8) 18.0 (6.1) 21.6 (6.9) 21.9 (7.8) 2.3 (1.49, 3.20); <0.001 
†† Calculated using sit-to-stand rather than 6-minute walk, due to space restrictions within GP surgeries 
¥ Regression models compared prevalent and incident cases only, adjusting for sex, age, smoking status and disease severity 
α Dependent variable treated as binary outcome (co-morbidities = none / 1 or more, exacerbations = none / 1 or more, weight status = underweight/not underweight, 
BODE = 0-2 / 3-10) 
 
 
